John R.  Liddicoat net worth and biography

John Liddicoat Biography and Net Worth

EVP of Medtronic
Dr. John Liddicoat was named Executive Vice President and President, Americas Region in September 2018, and serves as a member of the Medtronic Executive Committee.

Dr. Liddicoat joined Medtronic in 2006 as Vice President of Atrial Fibrillation Technologies. In December of 2006, John was named Vice President and General Manager of the Structural Heart Disease Business, which expanded his responsibilities to include the global operations of the surgical and transcatheter valve product portfolios. Soon thereafter, John assumed the leadership responsibilities of the entire Structural Heart business, and he was named the Senior Vice President and President of the Medtronic Structural Heart division. Under his leadership, the Structural Heart division doubled in revenue through a series of organic and acquisition activities.

Beginning in August 2014, Dr. Liddicoat served as Senior Vice President and President, Cardiac Rhythm and Heart Failure (CRHF) Division. In this role, he was responsible for the overall strategic direction and day-today global operations of five business units covering the diagnosis, treatment, and management of patients with cardiac dysrhythmias and heart failure with an annual revenue approaching $6B.

Dr. Liddicoat is a cardiothoracic surgeon who, prior to joining Medtronic, most recently practiced at the Beth Israel Deaconess Medical Center in Boston where he also held an appointment as Assistant Professor of Surgery at Harvard Medical School. John earned an MBA from Boston University, a doctor of medicine from the University of Chicago, and a bachelor’s degree from the University of Michigan. He completed his surgical training in general and cardiothoracic surgery at Johns Hopkins Hospital in Baltimore. Prior to joining Medtronic, Dr. Liddicoat founded two medical device companies, and served as a consultant to several venture capital firms and medical device companies.

How do I contact John R. Liddicoat?

The corporate mailing address for Liddicoat and other Medtronic executives is 20 ON HATCH LOWER HATCH STREET, DUBLIN L2, D02. Medtronic can also be reached via phone at (531) 438-1700 and via email at [email protected]. Learn More on John R. Liddicoat's contact information.

Has John R. Liddicoat been buying or selling shares of Medtronic?

John R. Liddicoat has not been actively trading shares of Medtronic during the last ninety days. Learn More on John R. Liddicoat's trading history.

Who are Medtronic's active insiders?

Medtronic's insider roster includes Richard Anderson (Director), Michael Coyle (EVP), Gary Ellis (EVP), Hooman Hakami (EVP), Bryan Hanson (EVP), Omar Ishrak (Chairman), Richard Kuntz (SVP), Bradley Lerman (SVP), John Liddicoat (EVP), Michael Marinaro (EVP), Geoffrey Martha (CEO), Karen Parkhill (CFO), Sean Salmon (EVP), Gregory Smith (EVP), Carol Surface (SVP), Rob Ten Hoedt (EVP), Brett Wall (EVP), Brett Wall (EVP), and Robert White (EVP). Learn More on Medtronic's active insiders.

Are insiders buying or selling shares of Medtronic?

During the last year, insiders at the medical technology company sold shares 7 times. They sold a total of 55,558 shares worth more than $4,712,507.68. The most recent insider tranaction occured on February, 21st when EVP Sean Salmon sold 30,695 shares worth more than $2,613,065.35. Insiders at Medtronic own 0.3% of the company. Learn More about insider trades at Medtronic.

Information on this page was last updated on 2/21/2024.

John R. Liddicoat Insider Trading History at Medtronic

See Full Table

John R. Liddicoat Buying and Selling Activity at Medtronic

This chart shows John R. Liddicoat's buying and selling at Medtronic by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Medtronic Company Overview

Medtronic logo
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company's Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company's Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies. The company was founded in 1949 and is headquartered in Dublin, Ireland.
Read More

Today's Range

Now: $86.92
Low: $84.10
High: $87.03

50 Day Range

MA: $85.21
Low: $83.08
High: $88.09

2 Week Range

Now: $86.92
Low: $68.84
High: $92.02

Volume

8,208,297 shs

Average Volume

6,301,624 shs

Market Capitalization

$115.41 billion

P/E Ratio

27.68

Dividend Yield

3.32%

Beta

0.76